White blood cell count combined with LDL cholesterol as a valuable biomarker for coronary artery disease.
Journal
Coronary artery disease
ISSN: 1473-5830
Titre abrégé: Coron Artery Dis
Pays: England
ID NLM: 9011445
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
10
8
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
ppublish
Résumé
Inflammation and dyslipidemia are important pathophysiological bases for the occurrence and development of coronary artery disease (CAD); however, combination of these two entities is rarely used to diagnose CAD and its severity. Our aim was to determine whether the combination of white blood cell count (WBCC) and LDL cholesterol (LDL-C) can serve as a biomarker for CAD. We enrolled 518 registered patients and measured serum WBCC and LDL-C on admission. The clinical data were collected, and the Gensini score was used to assess the severity of coronary atherosclerosis. WBCC and LDL-C levels in the CAD group were higher than in the control group ( P < 0.01). Spearman correlation analysis showed that WBCC combined with LDL-C was positively correlated with the Gensini score ( r = 0.708, P < 0.01) and the number of coronary artery lesions ( r = 0.721, P < 0.01). Receiver operating characteristic curve analysis revealed that WBCC combined with LDL-C had a higher predictive value for CAD, severe CAD, and three-vessel CAD [area under the curve (AUC) values were 0.909, 0.867, and 0.811, respectively] than WBCC (AUC values were 0.814, 0.753, 0.716, respectively) and LDL-C (AUC values were 0.779, 0.806, 0.715, respectively) alone (all P < 0.05). WBCC combined with LDL-C is correlated with the degree of coronary artery lesion. It had high sensitivity and specificity in the diagnosis of CAD, severe CAD, and three-vessel CAD.
Identifiants
pubmed: 37222213
doi: 10.1097/MCA.0000000000001248
pii: 00019501-990000000-00110
pmc: PMC10373838
doi:
Substances chimiques
Cholesterol, LDL
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
425-431Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res 2019; 124:315–327.
Nakanishi Y, Kang S, Kumanogoh A. Axon guidance molecules in immunometabolic diseases. Inflamm Regen 2022; 42:5.
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 2022; 145:e153–e639.
Sweetnam PM, Thomas HF, Yarnell JW, Baker IA, Elwood PC. Total and differential leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies. Am J Epidemiol 1997; 145:416–421.
Gillum RF, Ingram DD, Makuc DM. White blood cell count, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J 1993; 125:855–863.
Ates AH, Canpolat U, Yorgun H, Kaya EB, Sunman H, Demiri E, et al. Total white blood cell count is associated with the presence, severity and extent of coronary atherosclerosis detected by dual-source multislice computed tomographic coronary angiography. Cardiol J 2011; 18:371–377.
Chang TI, Wu X, Boström KI, Tran HA, Couto-Souza PH, Friedlander AH. Elevated white blood cell count resultant atherogenesis is associated with panoramic-imaged carotid plaque. J Oral Maxillofac Surg 2021; 79:1069–1073.
Won KB, Park GM, Yang YJ, Ann SH, Kim YG, Yang DH, et al. Independent role of low-density lipoprotein cholesterol in subclinical coronary atherosclerosis in the absence of traditional cardiovascular risk factors. Eur Heart J Cardiovasc Imaging 2019; 20:866–872.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145:e876–e894.
Alan B, Akpolat V, Aktan A, Alan S. Relationship between osteopenic syndrome and severity of coronary artery disease detected with coronary angiography and Gensini score in men. Clin Interv Aging 2016; 11:377–382.
Uysal HB, Dağli B, Akgüllü C, Avcil M, Zencir C, Ayhan M, et al. Blood count parameters can predict the severity of coronary artery disease. Korean J Intern Med 2016; 31:1093–1100.
Dugani SB, Moorthy MV, Li C, Demler OV, Alsheikh-Ali AA, Ridker PM, et al. Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident coronary heart disease in women. JAMA Cardiol 2021; 6:437–447.
Zhang Y, Pletcher MJ, Vittinghoff E, Clemons AM, Jacobs DR Jr, Allen NB, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol 2021; 6:1406–1413.
Kawabe A, Yasu T, Morimoto T, Tokushige A, Momomura SI, Sakakura K, et al.; CHD Collaborative Investigators. WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study. ESC Heart Fail 2021; 8:3748–3759.
Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al.; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104:1108–1113.
Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340:115–126.
Takahashi K, Takeya M, Sakashita N. Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals. Med Electron Microsc 2002; 35:179–203.
Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001; 88:3J–6J.
Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106:2894–2900.
Kaartinen M, van der Wal AC, van der Loos CM, Piek JJ, Koch KT, Becker AE, et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol 1998; 32:606–612.
Laine P, Kaartinen M, Penttilä A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999; 99:361–369.
Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2014; 114:1852–1866.
Palmerini T, Mehran R, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, et al. Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the harmonizing outcome with revascularization and stent in acute myocardial infarction trial. Circulation 2011; 123:2829–37, 7 p following 2837.
Zhao X, Jiang L, Xu L, Tian J, Xu Y, Zhao Y, et al. Predictive value of in-hospital white blood cell count in Chinese patients with triple-vessel coronary disease. Eur J Prev Cardiol 2019; 26:872–882.
Núñez JE, Núñez E, Bertomeu V, Fácila L, Sanchis J, Bodí V, et al. Prognostic value of baseline white blood cell count in patients with acute myocardial infarction and ST segment elevation. Heart 2005; 91:1094–1095.
Ono M, Tomaniak M, Koenig W, Khamis R, de Silva R, Chichareon P, et al. Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. Eur Heart J Cardiovasc Pharmacother 2022; 8:39–47.
Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart 2021; 107:1369–1375.
Zhou R, Stouffer GA, Smith SC Jr. Targeting the cholesterol paradigm in the risk reduction for atherosclerotic cardiovascular disease: does the mechanism of action of pharmacotherapy matter for clinical outcomes. J Cardiovasc Pharmacol Ther 2021; 26:533–549.
Luchetti F, Crinelli R, Nasoni MG, Benedetti S, Palma F, Fraternale A, et al. LDL receptors, caveolae and cholesterol in endothelial dysfunction: oxLDLs accomplices or victims. Br J Pharmacol 2021; 178:3104–3114.
Chistiakov DA, Myasoedova VA, Revin VV, Orekhov AN, Bobryshev YV. The phenomenon of atherosclerosis reversal and regression: lessons from animal models. Exp Mol Pathol 2017; 102:138–145.
Vani A, Underberg JA. Lowering LDL-cholesterol and CV benefits: is there a limit to how low LDL-C needs to be for optimal health benefits. Clin Pharmacol Ther 2018; 104:290–296.
Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin Chem 2021; 67:143–153.